Compare Stocks: SPRO, VNDA, EYPT, and PALI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYPT Eyepoint Pharmaceuticals	$3.46 +4.2%	$6.15	$3.05 ▼ $19.11	$286.22M	1.67	3.53 million shs	3.26 million shs
PALI Palisade Bio	$1.45 -2.0%	$1.88	$1.32 ▼ $2.86	$257.92M	1.61	3.86 million shs	2.08 million shs
SPRO Spero Therapeutics	$1.14 -2.6%	$1.20	$1.08 ▼ $3.08	$68.14M	1.5	888,055 shs	718,886 shs
VNDA Vanda Pharmaceuticals	$4.53 -0.7%	$5.14	$4.27 ▼ $9.94	$275.71M	0.69	1.14 million shs	966,279 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYPT Eyepoint Pharmaceuticals	+4.22%	+7.12%	-24.12%	-76.49%	-75.07%
PALI Palisade Bio	-2.03%	+1.40%	-34.09%	-26.02%	-27.50%
SPRO Spero Therapeutics	-2.56%	-9.52%	-4.20%	-45.71%	-50.00%
VNDA Vanda Pharmaceuticals	-0.66%	-5.82%	-15.01%	-27.40%	-17.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYPT Eyepoint Pharmaceuticals	$3.46 +4.2%	$6.15	$3.05 ▼ $19.11	$286.22M	1.67	3.53 million shs	3.26 million shs
PALI Palisade Bio	$1.45 -2.0%	$1.88	$1.32 ▼ $2.86	$257.92M	1.61	3.86 million shs	2.08 million shs
SPRO Spero Therapeutics	$1.14 -2.6%	$1.20	$1.08 ▼ $3.08	$68.14M	1.5	888,055 shs	718,886 shs
VNDA Vanda Pharmaceuticals	$4.53 -0.7%	$5.14	$4.27 ▼ $9.94	$275.71M	0.69	1.14 million shs	966,279 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYPT Eyepoint Pharmaceuticals	+4.22%	+7.12%	-24.12%	-76.49%	-75.07%
PALI Palisade Bio	-2.03%	+1.40%	-34.09%	-26.02%	-27.50%
SPRO Spero Therapeutics	-2.56%	-9.52%	-4.20%	-45.71%	-50.00%
VNDA Vanda Pharmaceuticals	-0.66%	-5.82%	-15.01%	-27.40%	-17.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	642.77% Upside
PALI Palisade Bio	3.00	Buy	$9.83	578.16% Upside
SPRO Spero Therapeutics	2.25	Hold	$6.00	426.32% Upside
VNDA Vanda Pharmaceuticals	2.44	Hold	$13.08	188.82% Upside

Current Analyst Ratings Breakdown

Latest SPRO, VNDA, EYPT, and PALI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	PALI Palisade Bio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
10/6/2026	VNDA Vanda Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
10/5/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/23/2026	VNDA Vanda Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
9/23/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/14/2026	SPRO Spero Therapeutics	Compass Point Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral
9/14/2026	SPRO Spero Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/14/2026	SPRO Spero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	EYPT Eyepoint Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYPT Eyepoint Pharmaceuticals	$31.37M	9.51	N/A	N/A	$3.70 per share	0.94
PALI Palisade Bio	$250K	1,010.77	N/A	N/A	$0.87 per share	1.67
SPRO Spero Therapeutics	$42.96M	1.55	$0.15 per share	7.69	$1.05 per share	1.09
VNDA Vanda Pharmaceuticals	$216.10M	1.27	N/A	N/A	$5.54 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)
SPRO Spero Therapeutics	$8.57M	$0.11	10.36	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest SPRO, VNDA, EYPT, and PALI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	EYPT Eyepoint Pharmaceuticals	-$0.9052	N/A	N/A	N/A	$0.23 million	N/A
11/4/2026	Q3 2026	VNDA Vanda Pharmaceuticals	-$0.72	N/A	N/A	N/A	$69.20 million	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	$0.06	5.26%	N/A	54.55%	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
PALI Palisade Bio	N/A	24.26	24.26
SPRO Spero Therapeutics	N/A	6.12	6.12
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYPT Eyepoint Pharmaceuticals	99.41%
PALI Palisade Bio	11.79%
SPRO Spero Therapeutics	25.60%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
EYPT Eyepoint Pharmaceuticals	5.13%
PALI Palisade Bio	0.07%
SPRO Spero Therapeutics	2.90%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable
SPRO Spero Therapeutics	25	58.24 million	56.55 million	Optionable
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable

SPRO, VNDA, EYPT, and PALI Headlines

Recent News About These Companies

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Bumped Down to "Strong Sell" by Zacks Research

October 8 at 6:06 AM | americanbankingnews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Zacks Research

October 8 at 6:05 AM | marketbeat.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as Buy by HC Wainwright

October 5, 2026 | marketbeat.com

Vanda Pharmaceuticals: Buy Rating Reaffirmed as HETLIOZ Phase 3 Success in DSWPD Supports sNDA; $20 Price Target Maintained

October 5, 2026 | tipranks.com

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

October 2, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 2, 2026 | americanbankingnews.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Analysts

October 2, 2026 | marketbeat.com

Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It

October 1, 2026 | seekingalpha.com

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

September 30, 2026 | msn.com

Vanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up

September 30, 2026 | rttnews.com

Vanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up

September 30, 2026 | rttnews.com

Vanda posts late-stage trial win for HETLIOZ in DSWPD, setting up another label expansion

September 30, 2026 | msn.com

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

September 29, 2026 | prnewswire.com

Vanda's Year-End Catalysts: Three Phase 3 Readouts And An FDA Decision Ahead

September 28, 2026 | rttnews.com

Vanda Pharmaceuticals Inc. $VNDA Stock Purchased by State Street Corp

September 26, 2026 | marketbeat.com

Oppenheimer initiates coverage of Vanda Pharmaceuticals with an outperform rating

September 23, 2026 | msn.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO, VNDA, EYPT, and PALI Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.46 +0.14 (+4.22%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$3.47 +0.01 (+0.29%)

As of 06:17 AM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Palisade Bio NASDAQ:PALI

$1.45 -0.03 (-2.03%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$1.48 +0.04 (+2.41%)

As of 05:52 AM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Spero Therapeutics NASDAQ:SPRO

$1.14 -0.03 (-2.56%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.16%)

As of 10/8/2026 07:30 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.53 -0.03 (-0.66%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$4.65 +0.12 (+2.65%)

As of 04:58 AM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, VNDA, EYPT, and PALI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, VNDA, EYPT, and PALI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, VNDA, EYPT, and PALI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO, VNDA, EYPT, and PALI Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

Palisade Bio NASDAQ:PALI

Spero Therapeutics NASDAQ:SPRO

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, VNDA, EYPT, and PALI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, VNDA, EYPT, and PALI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, VNDA, EYPT, and PALI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO, VNDA, EYPT, and PALI Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

Palisade Bio NASDAQ:PALI

Spero Therapeutics NASDAQ:SPRO

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools